MAST

The Happiest Place on Earth Is Opening Consumers’ Personal Data to Risk

Retrieved on: 
Wednesday, May 25, 2022
Software, Mobile, Wireless, Networks, Vacation, Data Management, Cruise, Other Travel, Consumer Electronics, Technology, Lodging, Destinations, Travel, Security, Work, Risk assessment, IOS, SpotHero, Environment, Uber, Policy, Parent, Solution, Organization, Southwest Airlines, Privacy, Â, Ownership, Research, MAST, App Store (iOS/iPadOS), Ride, Lyft, Compliance, Technology, Travel, BYOD, Satellite navigation device, Online shopping, Ridesharing company, Mobile phone

The apps, frequently used by consumers, include Disneyland, Uber, Southwest Airlines, Waze and SpotHero.

Key Points: 
  • The apps, frequently used by consumers, include Disneyland, Uber, Southwest Airlines, Waze and SpotHero.
  • In our new hybrid work environment, its not just personal devices coming along for the ride.
  • The lines continue to blur between personal bring your own device (BYOD) and professional devices, and its crucial employers and employees are aware of the potential risks.
  • The largest risks to consumers include breaches to privacy and personal data given the following access points to your devices:
    The results of this risk assessment raised several important concerns.

Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022

Retrieved on: 
Tuesday, May 17, 2022
Program, Risk, Houston, Death, McGovern Medical School, Constipation, DDW, Incidence, Cedars-Sinai Medical Center, Patient, Abdominal distension, IBS-C, Treatment, AGAF, Human, Diarrhea, MAST, RATS, FACG, FRCP, University of Texas Health Science Center at San Antonio, Safety, Nutrition, Dehydration, Irritable bowel syndrome, MD, CA, Pharmaceutical industry, Health insurance, Birth control, Technology, Gastroenterology

Avoid use of IBSRELA in patients 6 years to less than 12 years of age.

Key Points: 
  • Avoid use of IBSRELA in patients 6 years to less than 12 years of age.
  • The safety and effectiveness of IBSRELA have not been established in patients less than 18 years of age.
  • IBSRELA is contraindicated in patients less than 6 years of age due to the risk of serious dehydration.
  • The safety and effectiveness of IBSRELA in patients less than 18 years of age have not been established.

Kryptowire Identifies High Risk Security Vulnerability in Samsung Devices Running Android

Retrieved on: 
Tuesday, April 5, 2022
Security, Data Management, Mobile, Wireless, Technology, Software, Crime, Method, LinkedIn, Organization, Compliance, MAST, Privacy, CTO, HTTPS, SMR, Android, Solution, Android Pie, Mobile phone, Online shopping, Twitter, Samsung, KRYPTOWIRE MAST, KRYPTOWIRE INC.

Kryptowire Inc. , a mobile security and privacy solutions company, today announced it identified a serious security vulnerability ( CVE-2022-22292 ) in Samsung devices running Android versions 9 through 12.

Key Points: 
  • Kryptowire Inc. , a mobile security and privacy solutions company, today announced it identified a serious security vulnerability ( CVE-2022-22292 ) in Samsung devices running Android versions 9 through 12.
  • The vulnerability, discovered using Kryptowire Mobile Application Security Testing (MAST), allowed local applications to mimic system-level activity and hijack critical protected functionality.
  • The CVE-2022-22292 vulnerability was disclosed to Samsung on November 27, 2021 and given a High severity rating by Samsung.
  • The vulnerability resides in the pre-installed Phone app that executes with system privileges on Samsung devices running Android 9 through 12.

Kryptowire Identifies Security and Privacy Vulnerability in Mobile Device Chipset from China

Retrieved on: 
Tuesday, March 15, 2022
Solution, Face, IOS, Trust, Multimedia, Organization, MAST, AI, Compliance, Disclosure, Privacy, Android, Policy, LinkedIn, Satellite navigation device, Online shopping, Medical device, Twitter

MCLEAN, Va., March 15, 2022 /PRNewswire/ -- Kryptowire Inc., a mobile security and privacy solutions company, today announced that they have identified a critical security and privacy vulnerability affecting mobile devices with UNISOC, China's largest designer of chips for mobile phones. The vulnerability within the chipset, if exploited, allows malicious actors to take control over user data and device functionality. 

Key Points: 
  • Vulnerability enables outside access to user data, camera function, system logs, and device management
    MCLEAN, Va., March 15, 2022 /PRNewswire/ -- Kryptowire Inc., a mobile security and privacy solutions company, today announced that they have identified a critical security and privacy vulnerability affecting mobile devices with UNISOC, China's largest designer of chips for mobile phones.
  • The vulnerability within the chipset, if exploited, allows malicious actors to take control over user data and device functionality.
  • Adhering to its disclosure policy, Kryptowire notified affected device manufacturers and carriers, as well as UNISOC, of the vulnerability in December 2021.
  • Kryptowire is a leader in cloud-based mobile security and privacy solutions, delivering organizations and end-users the peace of mind that comes with intrusion-free mobile security.

Kryptowire Identifies Security and Privacy Vulnerability in Mobile Device Chipset from China

Retrieved on: 
Tuesday, March 15, 2022
Solution, Face, IOS, Trust, Organization, MAST, AI, Compliance, Disclosure, Privacy, Android, Policy, LinkedIn, Satellite navigation device, Online shopping, Medical device, Twitter

MCLEAN, Va., March 15, 2022 /PRNewswire/ -- Kryptowire Inc., a mobile security and privacy solutions company, today announced that they have identified a critical security and privacy vulnerability affecting mobile devices with UNISOC, China's largest designer of chips for mobile phones. The vulnerability within the chipset, if exploited, allows malicious actors to take control over user data and device functionality. 

Key Points: 
  • Vulnerability enables outside access to user data, camera function, system logs, and device management
    MCLEAN, Va., March 15, 2022 /PRNewswire/ -- Kryptowire Inc., a mobile security and privacy solutions company, today announced that they have identified a critical security and privacy vulnerability affecting mobile devices with UNISOC, China's largest designer of chips for mobile phones.
  • The vulnerability within the chipset, if exploited, allows malicious actors to take control over user data and device functionality.
  • Adhering to its disclosure policy, Kryptowire notified affected device manufacturers and carriers, as well as UNISOC, of the vulnerability in December 2021.
  • Kryptowire is a leader in cloud-based mobile security and privacy solutions, delivering organizations and end-users the peace of mind that comes with intrusion-free mobile security.

Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results

Retrieved on: 
Thursday, February 24, 2022
Prucalopride, Head, Elastography, Regulatory affairs, Company, Senior, Liver, Nasdaq, NAFLD, NASH, Knowledge, Private Securities Litigation Reform Act, Research, Judgement, U.S. Securities and Exchange Commission, Therapy, Gastroenterology, Cirrhosis, Risk, Memorial Sloan Kettering Cancer Center, SEC, Safety, Bristol Myers Squibb, MAST, Accelerated approval (FDA), Disclosure, Program, Doctor of Philosophy, IQVIA, NASDAQ, THR, MRE, Forward-looking statement, Patient, Eli Lilly and Company, Communication, Takeda, GLOBE, Fatty liver disease, Income, Achievement, Research and development, Fibrosis, Annual report, University, Clinical trial, Liver disease, FDA, ELF, Guidances for statistics in regulatory affairs, Time, Pharmaceutical industry, Medical imaging, Cryptocurrency, Madrigal

CONSHOHOCKEN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), today provides a summary of corporate accomplishments and reports its fourth quarter and full year 2021 financial results.

Key Points: 
  • CONSHOHOCKEN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), today provides a summary of corporate accomplishments and reports its fourth quarter and full year 2021 financial results.
  • The frequency of serious adverse events was similar across placebo and active treatment arms and discontinuation for adverse events was low.
  • Dr. Labriola has 35 years of experience in clinical development overseeing the global registration of 20 medicines.
  • Undue reliance should not be placed on forward- looking statements, which speak only as of the date they are made.

Kryptowire Receives Growth Investment from USVP and Crosslink Capital

Retrieved on: 
Wednesday, February 16, 2022
U.S. Venture Partners, Pluto TV, Adoption, HotelTonight, USVP, Cross-link, MAST, Health, Solution, Trunk Club, Silicon, General partnership, Android, Environment, ON24, Technology, IOS, Compliance, LinkedIn, Workforce, Guy-wire, Sequent, Privacy, Intersection, Growth, Crosslink Capital, RELX, Multimedia, Intersect ENT, Organization, Renewable energy, Online shopping, Luminate, Twitter

MCLEAN, Va., Feb. 16, 2022 /PRNewswire/ -- Kryptowire Inc., a mobile security and privacy solutions company, today announced a growth investment led by US Venture Partners (USVP), with participation from Crosslink Capital. The new funding will be used to accelerate the adoption of intrusion-free mobile security into targeted verticals – including healthcare, financial services and education – and support further product development.

Key Points: 
  • MCLEAN, Va., Feb. 16, 2022 /PRNewswire/ -- Kryptowire Inc., a mobile security and privacy solutions company, today announced a growth investment led by US Venture Partners (USVP), with participation from Crosslink Capital.
  • In 2021 alone, Kryptowire scanned over 3 billion lines of code across 70,000 applications, discovering over 500 vulnerabilities affecting approximately 2 billion devices.
  • Founded in 2011, Kryptowire developed and launched its Mobile Application Security Testing (MAST) service, leveraging its military-grade proprietary analysis engine.
  • U.S. Venture Partners (USVP) is a leading Silicon Valley venture capital firm, partnering with entrepreneurs to transform their ideas into world-changing companies.

Dominic F. Labriola Joins Madrigal Pharmaceuticals as Chief Data and Analytics Officer

Retrieved on: 
Monday, January 10, 2022
Clinical trial, Liver disease, Knowledge, Memorial Sloan Kettering Cancer Center, SEC, NAFLD, Safety, ELF, Disclosure, Risk, Head, Biostatistics, Liver, Fibrosis, CMO, Patient, Bristol Myers Squibb, NASDAQ, MRE, Health, Forward-looking statement, U.S. Securities and Exchange Commission, Annual report, MAST, Program, Time, Research, Senior, CEO, Private Securities Litigation Reform Act, Nasdaq, Communication, Fatty liver disease, THR, University, Judgement, Elastography, Cirrhosis, FDA, Therapy, Achievement, Accelerated approval (FDA), GLOBE, Non-alcoholic fatty liver disease, Pharmaceutical industry, Madrigal

CONSHOHOCKEN, Pa., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc.(NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, announced today that Dr. Dominic F. Labriola has joined Madrigal as Senior Vice President and Chief Data and Analytics Officer.

Key Points: 
  • CONSHOHOCKEN, Pa., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc.(NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, announced today that Dr. Dominic F. Labriola has joined Madrigal as Senior Vice President and Chief Data and Analytics Officer.
  • We are pleased to welcome Dr. Labriola to Madrigal at this pivotal time for the company, said Becky Taub, M.D., President R&D and CMO of Madrigal.
  • NASH is one of the major remaining unmet needs in medicine today, and data Madrigal will be generating in 2022 from the MAESTRO clinical trials have the potential to shape NASH patient care, said Dr. Labriola.
  • I am looking forward to contributing to the companys industry-leading NASH clinical development program as we work to deliver a transformational therapy for patients.

Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom

Retrieved on: 
Thursday, December 30, 2021
Safety, Non-alcoholic fatty liver disease, Private Securities Litigation Reform Act, Disclosure, Biomarker, U.S. Securities and Exchange Commission, Communication, ELF, FDA, Biopsy, Elastography, Clinical trial, GLOBE, MAST, Forward-looking statement, TG, Accelerated approval (FDA), NASDAQ, Magnetic resonance imaging, Liver disease, SEC, Knowledge, Fatty liver disease, Annual report, Patient, Research, Achievement, Therapy, MRE, Nasdaq, THR, Cirrhosis, Fibrosis, Liver, Judgement, Time, NAFLD, Risk, Pharmaceutical industry, Medical imaging, NAS, Madrigal

We now expect to announce topline 52-week results from the study in January 2022.

Key Points: 
  • We now expect to announce topline 52-week results from the study in January 2022.
  • Madrigal is currently conducting two Phase 3 Clinical trials, MAESTRO-NASH and MAESTRO-NAFLD-1, to demonstrate the safety and efficacy of resmetirom for the treatment of NASH.
  • MAESTRO-NASH is a Phase 3 multi-center, double-blind, randomized, placebo-controlled study of resmetirom in patients with liver biopsy confirmed NASH and was initiated in March 2019.
  • Patients in MAESTRO-NAFLD-1 are randomized 1:1:1 to receive resmetirom 80 mg once a day, 100 mg once a day, or placebo.

Kryptowire Collaborates with Orange and Uncovers Major Vulnerabilities in Mobile Devices at Scale

Retrieved on: 
Monday, December 13, 2021
OS, Group, Privacy, Technology, Compliance, OEM, Solution, Software, MAST, Trust, Security, Industry, Disclosure, Partnership, Risk, Medical device, Risk management, Online shopping, Orange

MCLEAN, Va., Dec. 13, 2021 /PRNewswire/ -- Kryptowire Inc., an enterprise mobile security and DevSecOps leader offering innovative, end-to-end cybersecurity solutions, today announced a successful collaboration with global telecommunications operator Orange wherein Kryptowire proactively identified a major security vulnerability present in several mobile devices in the market.

Key Points: 
  • MCLEAN, Va., Dec. 13, 2021 /PRNewswire/ -- Kryptowire Inc., an enterprise mobile security and DevSecOps leader offering innovative, end-to-end cybersecurity solutions, today announced a successful collaboration with global telecommunications operator Orange wherein Kryptowire proactively identified a major security vulnerability present in several mobile devices in the market.
  • As an industry leader committed to raising global standards for customer security and privacy, Orange is working with Kryptowire to audit the security of devices sold in their retail stores.
  • Kryptowire recently discovered a vulnerability affiliated with the AutoSLT application which is a system application used by several device manufacturers.
  • As a market leader in Mobile Application Security Testing (MAST), Kryptowire's proactive mobile security solutions ensure a higher-level of security and privacy for mobile apps and mobile devices.